Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by AB Science SA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate,Isoquercitrin

            Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: European Investment Bank

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 30, 2020

            Details:

            This agreement will enable AB Science to fund the clinical development programme evaluating masitinib as a treatment for COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AB1010

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 20, 2020

            Details:

            The pre-specified primary analysis was rate of severe asthma exacerbations, with masitinib demonstrating a statistically significant 29% reduction in severe exacerbations relative to placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AB1010

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            Details:

            Masitinib selectively targets mast cells through inhibition of tyrosine kinases c-Kit, LYN and FYN. Phase 3 study (AB07105) evaluating oral masitinib at 6 mg/kg/day versus placebo in severe asthma uncontrolled by oral corticosteroids (OCS) met its primary endpoint.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate

            Therapeutic Area: Neurology Product Name: AB1010

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 14, 2020

            Details:

            Masitinib, AB Science's lead product, is an oral tyrosine kinase inhibitor that specifically targets innate immunity of MS patients. Masitinib at a dose of 4.5 mg/kg/day slowed disease progression in patients, which was the study’s primary objective.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AB1010

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            Masitinib is a first in class oral drug in severe asthma, selectively targeting mast cells through inhibition of tyrosine kinases c-Kit, LYN and FYN.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate,Isoquercitrin

            Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 02, 2020

            Details:

            Starting from a library of 1,900 clinically used drugs, either approved for human use or in late stage clinical development, masitinib stood-out in its ability to completely inhibit activity of the SARS-CoV-2 main protease (3CLpro), thereby blocking viral replication.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate

            Therapeutic Area: Neurology Product Name: AB1010

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 08, 2020

            Details:

            The current research provides evidence suggesting that masitinib’s therapeutic efficacy is associated with a synapto-protective action in relation with mast cells inhibition.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AB8939

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 10, 2020

            Details:

            The therapeutic potential of AB8939 in AML is demonstrated using Ara-C resistant and azacitidine resistant patient-derived xenograft (PDX) models.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 07, 2020

            Details:

            The European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted AB Science phase 3 study AB07015 results with masitinib in severe asthma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate,Riluzole

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2020

            Details:

            Study AB19001 is an international Phase 3 study to compare the efficacy and safety of masitinib in combination with riluzole vs placebo in combination with riluzole in ALS.

            PharmaCompass